Advancing non-invasive healthcare through validated cfDNA solutions
Helping genomic healthcare professionals and researchers improve patient care.
See our range of liquid biopsy products below
Ensuring successful cell-free DNA analysis is our focus
Every sample is precious and to get the most out of your sample when evaluating cell-free DNA it is really critical to have processed your samples correctly from blood collection through to extracted cfDNA. Learn more about our Cell3™ Preserver blood tube and Cell3™ Xtract kit below.
Efficient workflow enables confident calling of all ctDNA mutations
Nonacus are working with some of the brightest scientists and clinicians by providing a validated complete workflow for liquid biopsy analysis. With the ultimate goal of enabling better cancer care through earlier diagnosis, treatment stratification and monitoring.
Non-invasive prenatal testing requires sensitive, reproducible and easy to use products
Nonacus continues to develop innovative products to meet these exacting standards including tests for fetal rhesus-D genotyping, fetal fraction quantitation and single gene disorder testing.
Who we are
Designed by scientists, for scientists
We are formed of a committed group of biotechnology professionals with a combined 35 years experience in genomic healthcare. We understand the pressure on laboratories to deliver progress and our products are designed to get you there. Between us, we’ve got global experience of genomic healthcare from the NHS in the UK through to an international genome project.
What we stand for
True innovation that benefits patients
We translate research into routine diagnostic tools that directly benefit patients and scientists. Our non-invasive cell-free DNA solutions improve diagnostic accuracy as well as the patient’s experience. Our research & development team are constantly developing, validating and testing new cfDNA products.
We supply Universities with our cfDNA products to help them improve their understanding and research in non-invasive healthcare.
Leading hospitals have adopted our products to help improve patient care through the innovative use of cfDNA technology allowing for non-invasive diagnostics.
We partner with many leading laboratories to constantly innovate and push our cfDNA products further.
Read our latest insights
Genetic testing company, Nonacus, has launched its latest next generation sequencing (NGS) test in the GALEAS product range – the GALEAS Hereditary Plus panel – which provides laboratories and clinicians with a comprehensive and streamlined way to diagnose patients with cancer that is caused by inherited genetic mutations.Read More
Hereditary cancer testing has become a valuable tool in healthcare, contributing to the understanding and identification of individuals’ susceptibility to cancer.Read More